title: The synthetic glucocorticoids prednisolone and dexamethasone regulate the same genes in acute lymphoblastic leukemia cells.
abstract: BACKGROUND
  Glucocorticoids (GCs) cause apoptosis in malignant cells of lymphoid lineage by transcriptionally regulating a plethora of genes. As a result, GCs are included in almost all treatment protocols for lymphoid malignancies, particularly childhood acute lymphoblastic leukemia (chALL). The most commonly used synthetic GCs in the clinical setting are prednisolone and dexamethasone. While the latter has a higher activity and more effectively reduces the tumor load in patients, it is also accompanied by more serious adverse effects than the former. Whether this difference might be explained by regulation of different genes by the two GCs has never been addressed.
  
  
  RESULTS
  Using a recently developed GC bioassay based on a GC-responsive reporter construct in human Jurkat T-ALL cells, we found ~7-fold higher biological activity with dexamethasone than prednisolone. Similarly, 1.0e-7 M dexamethasone and 7.0e-7 M prednisolone triggered similar cell death rates in CCRF-CEM-C7H2 T-chALL cells after 72 hours of treatment. Using microarray-based whole genome expression profiling and a variety of statistical and other approaches, we compared the transcriptional response of chALL cells to 6 hour exposure to both synthetic GCs at the above concentrations. Our experiments did not detect any gene whose regulation by dexamethasone differed significantly from that by prednisolone.
  
  
  CONCLUSIONS
  Our findings suggest that the reported differences in treatment efficacy and cytotoxicity of dexamethasone and prednisolone are not caused by inherent differences of the 2 drugs to regulate the expression of certain genes, but rather result either from applying them in biologically in-equivalent concentrations and/or from differences in their pharmacokinetics and - dynamics resulting in different bioactivities in tumor cells and normal tissues.
authors.forename: Daniel
authors.initials: D
authors.lastname: Bindreither
authors.forename: Simone
authors.initials: S
authors.lastname: Ecker
authors.forename: Barbara
authors.initials: B
authors.lastname: Gschirr
authors.forename: Anita
authors.initials: A
authors.lastname: Kofler
authors.forename: Reinhard
authors.initials: R
authors.lastname: Kofler
authors.affiliation: Division of Molecular Pathophysiology, Biocenter, Medical University Innsbruck, Innrain 80-82, 6020 Innsbruck, Austria. johannes.rainer@i-med.ac.at.
authors.forename: Johannes
authors.initials: J
authors.lastname: Rainer
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D002648:Child; D003907:Dexamethasone / Q000494:pharmacology*; D052138:Genes, Neoplasm / Q000187:drug effects*; D005938:Glucocorticoids / Q000494:pharmacology*; D006801:Humans; D019169:Jurkat Cells; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000473:pathology*; D011239:Prednisolone / Q000494:pharmacology*; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D005938:Glucocorticoids; D003907:Dexamethasone; D011239:Prednisolone
references.citation: Med Pediatr Oncol. 1996 Aug;27(2):114-21
references.pmid: 8649318
references.citation: Blood. 2006 Mar 1;107(5):2061-9
references.pmid: 16293608
references.citation: Semin Hematol. 2009 Jan;46(1):52-63
references.pmid: 19100368
references.citation: Endocr Rev. 2012 Apr;33(2):271-99
references.pmid: 22433123
references.citation: Cell Death Differ. 2001 Feb;8(2):201-3
references.pmid: 11313722
references.citation: J Clin Endocrinol Metab. 1975 Jun;40(6):1073-7
references.pmid: 1133157
references.citation: Lancet Oncol. 2012 Sep;13(9):906-15
references.pmid: 22901620
references.citation: Cancer Res. 1995 Jan 15;55(2):348-53
references.pmid: 7812967
references.citation: J Mol Signal. 2009 Sep 02;4:6
references.pmid: 19725972
references.citation: Mol Endocrinol. 2012 Jan;26(1):178-93
references.pmid: 22074950
references.citation: Leukemia. 2011 Aug;25(8):1232-8
references.pmid: 21527934
references.citation: Wien Klin Wochenschr. 2011 Apr;123(7-8):222-9
references.pmid: 21465082
references.citation: Oncogene. 1997 Nov 13;15(20):2429-37
references.pmid: 9395239
references.citation: Leuk Res. 2010 Apr;34(4):529-34
references.pmid: 19631983
references.citation: Am J Med. 1977 Aug;63(2):200-7
references.pmid: 888843
references.citation: Lancet Oncol. 2010 Nov;11(11):1096-106
references.pmid: 20947430
references.citation: Recent Prog Horm Res. 2003;58:175-97
references.pmid: 12795419
references.citation: BMC Genomics. 2013 Dec 01;14:844
references.pmid: 24289529
references.citation: Br J Haematol. 2010 Jun;149(5):638-52
references.pmid: 20408842
references.citation: Genome Biol. 2004;5(10):R80
references.pmid: 15461798
references.citation: Lancet. 2008 Mar 22;371(9617):1030-43
references.pmid: 18358930
references.citation: Mol Cell Endocrinol. 2007 Sep 15;275(1-2):13-29
references.pmid: 17689856
references.citation: Leuk Res. 2009 Dec;33(12):1684-95
references.pmid: 19450877
references.citation: Cancer Res. 1981 Oct;41(10):3979-84
references.pmid: 7285007
references.citation: Lancet. 2013 Jun 1;381(9881):1943-55
references.pmid: 23523389
references.citation: Leukemia. 2004 Nov;18(11):1850-6
references.pmid: 15385927
references.citation: Nat Rev Cancer. 2012 Nov;12(11):776-82
references.pmid: 23051845
references.citation: Haematologica. 2007 Nov;92(11):1460-9
references.pmid: 18024393
references.citation: J Clin Oncol. 1987 Feb;5(2):202-7
references.pmid: 3806166
references.citation: Stat Appl Genet Mol Biol. 2004;3:Article3
references.pmid: 16646809